Sunesis Pharmaceuticals, Inc.
(NASDAQ : SNSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.55%89.141.3%$797.85m
AMGNAmgen Inc.
1.08%187.501.2%$644.97m
GILDGilead Sciences, Inc.
0.29%65.740.9%$476.37m
BIIBBiogen Inc.
1.30%325.331.3%$432.61m
ILMNIllumina, Inc.
1.41%301.063.5%$311.78m
REGNRegeneron Pharmaceuticals, Inc.
0.93%422.522.6%$280.54m
VRTXVertex Pharmaceuticals Incorporated
1.48%185.761.9%$246.69m
ALXNAlexion Pharmaceuticals, Inc.
1.71%129.732.0%$214.36m
SRPTSarepta Therapeutics, Inc.
2.52%139.9815.4%$157.00m
AAgilent Technologies, Inc.
0.67%78.411.6%$155.05m
EXASExact Sciences Corporation
10.52%92.0425.3%$150.72m
INCYIncyte Corporation
1.82%84.852.5%$112.02m
ARRYArray BioPharma Inc.
2.33%23.248.2%$111.41m
NBIXNeurocrine Biosciences, Inc.
2.07%78.915.1%$80.47m
EXELExelixis, Inc.
1.41%21.526.4%$79.74m

Company Profile

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.